CTOs on the Move

Anox Kaldnes Inc

www.kaldnes.com

 
Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.kaldnes.com
  • 58 Weybosset St
    Providence, RI USA 02903
  • Phone: 401.270.3898

Executives

Name Title Contact Details

Similar Companies

Orchestra BioMed

Orchestra BioMed is a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asklepios BioPharmaceutical

Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders.

The Valens Company

The Valens Company (TSX:VLNS) (OTCQX:VLNCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development. The Valens Company is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.

AltPep

AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).